Keming Zhou is the founder of Vivatides Therapeutics. Vivatides Therapeutics has raised $54M in total funding. Latest round: Series A.
Keming Zhou is the founder of Vivatides Therapeutics, a biotechnology company focused on developing extrahepatic RNA-targeting therapeutics. The company secured an oversubscribed $54 million Series A financing to advance its extrahepatic delivery platform and pipeline.
Full founder directory · Investor directory · Company funding database · Fundraising library